Date: 2018-04-17
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Innate Pharma (France)
Product: IPH52 and IPH53
Action
mechanism: monoclonal antibody - immune checkpoint inhibitor
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On April 17, 2018, Innate Pharma announced that new preclinical data of its portfolio of next generation
immunotherapies have been presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, in Chicago. Regarding IPH52 and IPH53, anti-CD39 and anti-CD73 neutralizing antibodies targeting the ATP/Adenosine immune checkpoint pathway, preclinical data (ID: 2718) support their development for cancer immunotherapy, potentially in combination with chemotherapy or immune checkpoint blockade.
- These antibodies potently inhibit the enzymatic activity of both the soluble and membrane associated
forms of their respective target enzymes. In vitro, both antibodies efficiently reverse adenosine-mediated T cell suppression in the presence of ATP. IPH52, a first-in-class
CD39 blocking antibody, sustains high concentrations of extracellular ATP that promotes immune responses by enhancing dendritic cell (DC) activation and subsequent T cell
proliferation. IPH53 is more potent in vitro than benchmark anti-CD73 antibodies currently under clinical development. Additionally, combining IPH52 and IPH53 lead to a strong
reversion of immune cell inhibition in the presence of ATP. Humanized IPH52 and IPH53 are currently in preclinical development.
Is
general: Yes
